Johns Hopkins
This article was originally published in The Tan Sheet
Executive Summary
List of clinical trials that must be halted or reviewed due to HHS Office of Human Research Protections degree will be available by Aug. 10, university says. OHRP ruled July 19 that all human studies must be suspended after healthy patient died in trial June 2. However, office approved a corrective action plan July 21 that permits only human research studies eligible for expedited review, that were reviewed and approved in past year or that are ongoing and "in the best interests of the individual subjects" to resume. In October, NCCAM granted $7.8 mil. over five years to fund Hopkins Center for Complementary & Alternative Medicine in Cancer. JHU researchers also were conducting trials on OTC drugs and dietary supplements, including four-year study on glucosamine, chondrotin and knee osteoarthritis. Until list is released Aug. 10, it remains unclear whether these trials will be affected by OHRP/Hopkins compromise